Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 17/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 17/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.79 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329403 | 1.00 | HDAC1 (0.79) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2328005 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2328001 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2326986 | 0.88 | HDAC8 (0.78) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2322509 | 0.88 | HDAC3 (1.00) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2326946 | 0.88 | HDAC8 (0.78) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2322491 | 0.88 | HDAC3 (1.00) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2325915 | 0.87 | HDAC4 (0.78) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2325912 | 0.87 | HDAC4 (0.78) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL2325923 | 0.86 | HDAC1 (0.82) | HDAC1HDAC8HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2012-05-10 | — | — | US | claimed |
| EP-2197854-B1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC SRL (IT) | 2011-08-10 | — | — | EP | claimed |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-12-02 | — | — | US | claimed |
| EP-2033956-A1 | A new class of histone deacetylase inhibitors | DAC S.r.l. (IT) | 2009-03-11 | — | — | EP | claimed |
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| EP-2197854-B1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC SRL (IT) | 2011-08-10 | — | — | EP | disclosed |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| EP-2197854-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.l. (IT) | 2010-06-23 | — | — | EP | disclosed |
| EP-2033956-A1 | A new class of histone deacetylase inhibitors | DAC S.r.l. (IT) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885HDAC8 14/4885HDAC6 15/4885 |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC8 12/4885HDAC6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.